Kummermehr, J. & Trott, K.-R. in Stem Cells (ed. Potten, C. S.) 363–399 (Academic, 1997). Book Google Scholar
Reya, T., Morrison, S. J., Clarke, M. F. & Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature414, 105–111 (2001). ArticleADSCASPubMed Google Scholar
Shackleton, M., Quintana, E., Fearon, E. R. & Morrison, S. J. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell138, 822–829 (2009). ArticleCASPubMed Google Scholar
Clevers, H. The cancer stem cell: premises, promises and challenges. Nature Med.17, 313–319 (2011). ArticleCASPubMed Google Scholar
Bao, S. et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature444, 756–760 (2006). ArticleADSCASPubMed Google Scholar
Oravecz-Wilson, K. I. et al. Persistence of leukemia-initiating cells in a conditional knockin model of an imatinib-responsive myeloproliferative disorder. Cancer Cell16, 137–148 (2009). ArticleCASPubMedPubMed Central Google Scholar
Balic, M. et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin. Cancer Res.12, 5615–5621 (2006). ArticleCASPubMed Google Scholar
Magee, J. A., Piskounova, E. & Morrison, S. J. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell21, 283–296 (2012). ArticleCASPubMedPubMed Central Google Scholar
Charles, N. et al. Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell6, 141–152 (2010). ArticleCASPubMed Google Scholar
Calabrese, C. et al. A perivascular niche for brain tumor stem cells. Cancer Cell11, 69–82 (2007). ArticleCASPubMed Google Scholar
Quintana, E. et al. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell18, 510–523 (2010). This article reports that many phenotypically diverse melanoma cells are capable of forming tumours that recapitulate the surface marker heterogeneity of the tumour from which they derive, suggesting that there may not be a hierarchy of tumorigenic and non-tumorigenic cells in melanoma. ArticleCASPubMedPubMed Central Google Scholar
Roesch, A. et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell141, 583–594 (2010). ArticleCASPubMedPubMed Central Google Scholar
Pinner, S. et al. Intravital imaging reveals transient changes in pigment production and Brn2 expression during metastatic melanoma dissemination. Cancer Res.69, 7969–7977 (2009). ArticleCASPubMedPubMed Central Google Scholar
Sharma, S. V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell141, 69–80 (2010). This article reports that the acquisition of tolerance to therapeutics is transient and reversible in lung cancer cell lines raising the possibility that there are epigenetic mechanisms of therapy resistance that do not necessarily have anything to do with stem-cell identity or static hierarchies. ArticleCASPubMedPubMed Central Google Scholar
Chen, J. et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature488, 522–526 (2012). Using a mouse model of malignant glioma, the authors of this study report that selective ablation of Nestin+ glioma cells suggests that a relatively quiescent cell population sustains tumour growth after therapy. ArticleADSCASPubMedPubMed Central Google Scholar
Driessens, G., Beck, B., Caauwe, A., Simons, B. D. & Blanpain, C. Defining the mode of tumour growth by clonal analysis. Nature488, 527–530 (2012). Lineage tracing in a mouse model of benign papilloma shows that only a fraction of papilloma cells sustainably contribute to tumour growth, although the frequency of such cells increases drastically on progression to squamous cell carcinoma. ArticleADSCASPubMedPubMed Central Google Scholar
Schepers, A. G. et al. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science337, 730–735 (2012). Fate mapping of Lgr5+ cells in intestinal adenomas shows that these cells contribute to tumour growth while also forming Lgr5−progeny, raising the possibility that some adenomas are hierarchically organized. ArticleADSCASPubMed Google Scholar
Schwitalla, S. et al. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell152, 25–38 (2013). This study shows that both Lgr5+ and Lgr5−cells within intestinal adenomas are capable of forming tumours that are heterogeneous for Lgr5, suggesting that some adenomas may not be hierarchically organized. ArticleCASPubMed Google Scholar
Nakanishi, Y. et al. Dclk1 distinguishes between tumor and normal stem cells in the intestine. Nature Genet.45, 98–103 (2013). ArticleCASPubMed Google Scholar
Anderson, K. et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature469, 356–361 (2011). ArticleADSCASPubMed Google Scholar
Ding, L. et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature481, 506–510 (2012). By sequencing samples from patients with AML before and after therapy, this study shows that new genetic variants commonly emerge after therapy, suggesting that therapy resistance is commonly determined by genetic variants. ArticleADSCASPubMedPubMed Central Google Scholar
Xu, X. et al. Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell148, 886–895 (2012). ArticleCASPubMedPubMed Central Google Scholar
Lapidot, T. et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature367, 645–648 (1994). ArticleADSCASPubMed Google Scholar
Bonnet, D. & Dick, J. E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Med.3, 730–737 (1997). ArticleCASPubMed Google Scholar
Wang, J. C. et al. High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase. Blood91, 2406–2414 (1998). ArticleCASPubMed Google Scholar
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. & Clarke, M. F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA100, 3983–3988 (2003). ArticleADSCASPubMedPubMed Central Google Scholar
Singh, S. K. et al. Identification of human brain tumour initiating cells. Nature432, 396–401 (2004). ArticleADSCASPubMed Google Scholar
O'Brien, C. A., Pollett, A., Gallinger, S. & Dick, J. E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature445, 106–110 (2007). ArticleADSCASPubMed Google Scholar
Ricci-Vitiani, L. et al. Identification and expansion of human colon-cancer-initiating cells. Nature445, 111–115 (2007). ArticleADSCASPubMed Google Scholar
Li, C. et al. Identification of pancreatic cancer stem cells. Cancer Res.67, 1030–1037 (2007). ArticleCASPubMed Google Scholar
Curley, M. D. et al. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells27, 2875–2883 (2009). ArticleCASPubMed Google Scholar
Zhang, S. et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res.68, 4311–4320 (2008). ArticleCASPubMedPubMed Central Google Scholar
Stewart, J. M. et al. Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells. Proc. Natl Acad. Sci. USA108, 6468–6473 (2011). This study demonstrates that CD133 enriches tumorigenic cells in only a subset of ovarian cancers and that even in these tumours the effectiveness of the marker changes on passaging. ArticleADSCASPubMedPubMed Central Google Scholar
Kennedy, J. A., Barabe, F., Poeppl, A. G., Wang, J. C. & Dick, J. E. Comment on “Tumor growth need not be driven by rare cancer stem cells”. Science318, 1722 (2007). ArticleADSCASPubMed Google Scholar
Shultz, L. D., Ishikawa, F. & Greiner, D. L. Humanized mice in translational biomedical research. Nature Rev. Immunol.7, 118–130 (2007). ArticleCAS Google Scholar
Taussig, D. C. et al. Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood112, 568–575 (2008). ArticleCASPubMed Google Scholar
Notta, F. et al. Evolution of human BCR–ABL1 lymphoblastic leukaemia-initiating cells. Nature469, 362–367 (2011). ArticleADSCASPubMed Google Scholar
Chiu, P. P., Jiang, H. & Dick, J. E. Leukemia-initiating cells in human T-lymphoblastic leukemia exhibit glucocorticoid resistance. Blood116, 5268–5279 (2010). ArticleCASPubMed Google Scholar
Buchstaller, J., McKeever, P. E. & Morrison, S. J. Tumorigenic cells are common in mouse MPNSTs but their frequency depends upon tumor genotype and assay conditions. Cancer Cell21, 240–252 (2012). ArticleCASPubMedPubMed Central Google Scholar
Manz, M. G. Human-hemato-lymphoid-system mice: opportunities and challenges. Immunity26, 537–541 (2007). ArticleCASPubMed Google Scholar
Kuperwasser, C. et al. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc. Natl Acad. Sci. USA101, 4966–4971 (2004). ArticleADSCASPubMedPubMed Central Google Scholar
Kleinsmith, L. J. & Pierce, G. B. Multipotentiality of single embryonal carcinoma cells. Cancer Res.24, 1544–1551 (1964). CASPubMed Google Scholar
Yilmaz, O. H. et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature441, 475–482 (2006). ArticleADSCASPubMed Google Scholar
Krivtsov, A. V. et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9. Nature442, 818–822 (2006). ArticleADSCASPubMed Google Scholar
Vaillant, F. et al. The mammary progenitor marker CD61/β3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis. Cancer Res.68, 7711–7717 (2008). ArticleCASPubMed Google Scholar
Zhang, M. et al. Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res.68, 4674–4682 (2008). ArticleCASPubMedPubMed Central Google Scholar
Read, T. A. et al. Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma. Cancer Cell15, 135–147 (2009). ArticleCASPubMedPubMed Central Google Scholar
Ward, R. J. et al. Multipotent CD15+ cancer stem cells in patched-1-deficient mouse medulloblastoma. Cancer Res.69, 4682–4690 (2009). ArticleMathSciNetCASPubMed Google Scholar
Kelly, P. N., Dakic, A., Adams, J. M., Nutt, S. L. & Strasser, A. Tumor growth need not be driven by rare cancer stem cells. Science317, 337 (2007). ArticleADSCASPubMed Google Scholar
Held, M. A. et al. Characterization of melanoma cells capable of propagating tumors from a single cell. Cancer Res.70, 388–397 (2010). ArticleCASPubMedPubMed Central Google Scholar
Williams, R. T., den Besten, W. & Sherr, C. J. Cytokine-dependent imatinib resistance in mouse BCR-ABL+, _Arf_-null lymphoblastic leukemia. Genes Dev.21, 2283–2287 (2007). ArticleCASPubMedPubMed Central Google Scholar
Rehe, K. et al. Acute B lymphoblastic leukaemia-propagating cells are present at high frequency in diverse lymphoblast populations. EMBO Mol. Med.5, 38–51 (2013). ArticleCASPubMed Google Scholar
Feuring-Buske, M. et al. Improved engraftment of human acute myeloid leukemia progenitor cells in β 2-microglobulin-deficient NOD/SCID mice and in NOD/SCID mice transgenic for human growth factors. Leukemia17, 760–763 (2003). ArticleCASPubMed Google Scholar
Notta, F., Doulatov, S. & Dick, J. E. Engraftment of human hematopoietic stem cells is more efficient in female NOD/SCID/IL-2Rgc-null recipients. Blood115, 3704–3707 (2010). ArticleCASPubMed Google Scholar
Eppert, K. et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nature Med.17, 1086–1093 (2011). The authors of this study demonstrated that the frequency and surface marker phenotype of leukaemic stem cells varied among samples from 16 patients. ArticleCASPubMed Google Scholar
Civenni, G. et al. Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. Cancer Res.71, 3098–3109 (2011). ArticleCASPubMed Google Scholar
Chen, R. et al. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell17, 362–375 (2010). ArticleCASPubMed Google Scholar
Joo, K. M. et al. Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Lab. Invest.88, 808–815 (2008). ArticleCASPubMed Google Scholar
Wang, J. et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int. J. Cancer122, 761–768 (2008). ArticleCASPubMed Google Scholar
Beier, D. et al. CD133+ and CD133− glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res.67, 4010–4015 (2007). ArticleCASPubMed Google Scholar
Sarry, J. E. et al. Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice. J. Clin. Invest.121, 384–395 (2011). ArticleCASPubMed Google Scholar
Taussig, D. C. et al. Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34− fraction. Blood115, 1976–1984 (2010). ArticleCASPubMedPubMed Central Google Scholar
Curtis, S. J. et al. Primary tumor genotype is an important determinant in identification of lung cancer propagating cells. Cell Stem Cell7, 127–133 (2010). ArticleCASPubMedPubMed Central Google Scholar
Cozzio, A. et al. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev.17, 3029–3035 (2003). ArticleCASPubMedPubMed Central Google Scholar
Somervaille, T. C. & Cleary, M. L. Identification and characterization of leukemia stem cells in murine MLL–AF9 acute myeloid leukemia. Cancer Cell10, 257–268 (2006). ArticleCASPubMed Google Scholar
Huntly, B. J. et al. MOZ–TIF2, but not BCR–ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell6, 587–596 (2004). ArticleCASPubMed Google Scholar
Krivtsov, A. V. et al. Cell of origin determines clinically relevant subtypes of MLL-rearranged AML. Leukemia27, 852–860 (2013). ArticleCASPubMed Google Scholar
Hanahan, D. & Coussens, L. M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell21, 309–322 (2012). ArticleCASPubMed Google Scholar
Kreso, A. et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science339, 543–548 (2013). ArticleADSCASPubMed Google Scholar
Mascre, G. et al. Distinct contribution of stem and progenitor cells to epidermal maintenance. Nature489, 257–262 (2012). ArticleADSCASPubMed Google Scholar
Barker, N. et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature449, 1003–1007 (2007). ArticleADSCASPubMed Google Scholar
Gupta, P. B. et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell146, 633–644 (2011). ArticleCASPubMed Google Scholar
Marusyk, A., Almendro, V. & Polyak, K. Intra-tumour heterogeneity: a looking glass for cancer? Nature Rev. Cancer12, 323–334 (2012). ArticleCAS Google Scholar
Schuh, A. et al. Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. Blood120, 4191–4196 (2012). ArticleCASPubMed Google Scholar
Shah, S. P. et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature486, 395–399 (2012). ArticleADSCASPubMed Google Scholar
Nik-Zainal, S. et al. The life history of 21 breast cancers. Cell149, 994–1007 (2012). Whole-genome sequencing of breast cancers revealed extensive genetic variation within tumours, suggesting that no tumorigenic breast cancer cell could recapitulate the heterogeneity of the tumour from which it derives. ArticleCASPubMedPubMed Central Google Scholar
Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med.366, 883–892 (2012). ArticleCASPubMedPubMed Central Google Scholar
le Viseur, C. et al. In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell14, 47–58 (2008). ArticleCASPubMedPubMed Central Google Scholar
de Thé, H. & Chen, Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nature Rev. Cancer10, 775–783 (2010). ArticleCAS Google Scholar
Piccirillo, S. G. et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature444, 761–765 (2006). ArticleADSCASPubMed Google Scholar
Gross, R. E. et al. Bone morphogenetic proteins promote astroglial lineage commitment by mammalian subventricular zone progenitor cells. Neuron17, 595–606 (1996). ArticleCASPubMed Google Scholar
Thiele, C. J., Reynolds, C. P. & Israel, M. A. Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature313, 404–406 (1985). ArticleADSCASPubMed Google Scholar
Matthay, K. K. et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-_cis_-retinoic acid. N. Engl. J. Med.341, 1165–1173 (1999). ArticleCASPubMed Google Scholar
Garraway, L. A. & Janne, P. A. Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov.2, 214–226 (2012). ArticleCASPubMed Google Scholar
Tzoneva, G. et al. Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nature Med.19, 368–371 (2013). ArticleCASPubMed Google Scholar
Meyer, J. A. et al. Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nature Genet.45, 290–294 (2013). ArticleCASPubMed Google Scholar
Corbin, A. S. et al. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR–ABL activity. J. Clin. Invest.121, 396–409 (2011). ArticleCASPubMed Google Scholar
Graham, S. M. et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood99, 319–325 (2002). ArticleCASPubMed Google Scholar
Jiang, X. et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia21, 926–935 (2007). ArticleCASPubMed Google Scholar
Bhatia, R. et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood101, 4701–4707 (2003). ArticleCASPubMed Google Scholar
Rousselot, P. et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood109, 58–60 (2007). ArticleCASPubMed Google Scholar
Savona, M. & Talpaz, M. Getting to the stem of chronic myeloid leukaemia. Nature Rev. Cancer8, 341–350 (2008). ArticleCAS Google Scholar
Gorre, M. E. et al. Clinical resistance to STI–571 cancer therapy caused by BCR_–_ABL gene mutation or amplification. Science293, 876–880 (2001). ArticleCASPubMed Google Scholar
Shah, N. P. et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell2, 117–125 (2002). ArticleCASPubMed Google Scholar